Evidence map›Paper›PMID 34519167›Full record

ArticleActa ophthalmologica2022

12-month outcomes of ranibizumab versus aflibercept for macular oedema in central retinal vein occlusion: data from the FRB! registry.

Mateusz Niedzwiecki, Adrian Hunt, Vuong Nguyen, Hemal Mehta, Catherine Creuzot-Garcher, Pierre-Henry Gabrielle, Martin Guillemin, Samantha Fraser-Bell, Jennifer Arnold, Ian L McAllister and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta ophthalmologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Observational
  4. Observational
  5. Article
  6. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 5 countries.

Mateusz NiedzwieckiDepartment of Ophthalmology, University Hospital Zurich & University of Zurich, Zurich, Switzerland.
Adrian HuntDepartment of Ophthalmology, Westmead Hospital, Westmead, NSW, Australia.ORCID https://orcid.org/0000-0002-6261-4679
Vuong NguyenThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Hemal MehtaThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Catherine Creuzot-GarcherDepartment of Ophthalmology, Dijon University Hospital, Dijon, France.
Pierre-Henry GabrielleThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.ORCID https://orcid.org/0000-0002-9688-4845
Martin GuilleminDepartment of Ophthalmology, Dijon University Hospital, Dijon, France.
Samantha Fraser-BellThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Jennifer ArnoldMarsden Eye Specialists, Parramatta, NSW, Australia.
Ian L McAllisterCentre for Ophthalmology and Visual Science, Lions Eye Institute, The University of Western Australia, Perth, WA, Australia.
Mark GilliesThe Save Sight Institute, Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.
Daniel BarthelmesDepartment of Ophthalmology, University Hospital Zurich & University of Zurich, Zurich, Switzerland.
The University of Sydney · AUMaison des Sciences sociales et des Humanités de Dijon · FRHazleton Eye Specialists · USLions Eye Institute · AUUniversity of Zurich · CH

Funding

National Health and Medical Research Council NHMRC 2010-1012Royal Australian and New Zealand College of Ophthalmologists 2007-2009
6 · The paper itself

Abstract

purposeTo compare 12-month treatment outcomes of eyes receiving aflibercept or ranibizumab for macular oedema secondary to central retinal vein occlusion (CRVO) in routine clinical practice.

methods296 treatment-naïve eyes receiving either aflibercept (171 eyes, 2 mg) or ranibizumab (125 eyes, 0.5 mg) for macular oedema secondary to CRVO were recruited retrospectively from centres using the prospectively designed FRB! registry. The primary outcome measure was the mean change in LogMAR letter scores of visual acuity (VA). Secondary outcomes included change in central subfield thickness (CST), injections and visits, time to first grading of inactivity, switching and non-completion from baseline to 12 months.

resultsBaseline VA (SD) was somewhat better in aflibercept- versus ranibizumab-treated eyes (42.5 ± 25.5 letters versus 36.9 ± 26 letters; p = 0.07) with similar CST (614 (240) μm versus 616 (234) μm: p = 0.95). The 12-month adjusted mean (95%CI) VA change was +16.6 (12.9, 20.4) letters for aflibercept versus +9.8 (5.5, 14.1) letters for ranibizumab (p = 0.001). The mean (95%CI) adjusted change in CST was significantly greater in aflibercept- versus ranibizumab-treated eyes: -304 (-276, -333) µm versus -252 (-220, -282) µm (p < 0.001). Both groups had a median (Q1, Q3) of 7 (5, 9) injections and 10 (8,13) visits. Aflibercept-treated eyes became inactive sooner than ranibizumab (p = 0.02). Switching occurred more commonly from ranibizumab (26 eyes, 21%) than from aflibercept (9 eyes, 5%) (p < 0.001).

conclusionBoth aflibercept and ranibizumab improved VA and reduced CST in eyes with CRVO in routine clinical practice, with aflibercept showing significantly greater improvements in this comparative analysis.

Indexed as

Macular EdemaRetinal Vein OcclusionAngiogenesis InhibitorsHumansIntravitreal InjectionsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsRegistriesRetrospective StudiesVascular Endothelial Growth Factor AafliberceptAngiogenesis InhibitorsRanibizumabReceptors, Vascular Endothelial Growth FactorRecombinant Fusion ProteinsVascular Endothelial Growth Factor AafliberceptCRVOcystoidmaculaoedemaranibizumab

Identifiers

PMID34519167
PMCPMC9292733
OpenAlexW3200955316

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.